The TP53 gene belongs to routinely tested breast cancer predisposition genes, regardless of the rarity of its germline variants, which are two orders of magnitude less frequent than those in BRCA2 (0.06% vs. 1.29% and 0.014% vs. 1.54%, respectively), as demonstrated in the largest breast cancer studies by Hu et al. and the Breast Cancer Association Consortium27,28. This evidence concerns the gene BRCA2 and breast carcinoma.